HRPC(SH:600829)2016-04-22 16:00Financial Performance - Operating revenue for the reporting period was CNY 2,303,847,455.63, down 14.85% from CNY 2,705,616,840.18 in the same period last year[6] - Net profit attributable to shareholders of the listed company was CNY 62,876,371.66, an increase of 3.42% compared to CNY 60,799,320.80 in the previous year[6] - The company's basic and diluted earnings per share were both CNY 0.1101, reflecting a 1.29% increase from CNY 0.1087 in the previous year[6] - Total operating revenue for Q1 2016 was CNY 2,303,847,455.63, a decrease of 14.8% compared to CNY 2,705,616,840.18 in the same period last year[27] - Net profit for Q1 2016 reached CNY 63,817,318.13, an increase of 12.0% compared to CNY 56,664,896.24 in the previous year[28] - Basic and diluted earnings per share for Q1 2016 were CNY 0.0038, down from CNY 0.0640 year-over-year[30] Cash Flow - Cash flow from operating activities showed a significant improvement, with a net cash flow of CNY 9,685,749.82 compared to a negative CNY 99,736,777.10 in the same period last year[6] - Operating cash flow for the current period is 9,685,749.82, a substantial increase compared to -99,736,777.10 in the previous year, mainly driven by increased sales collections and reduced inventory[16] - Net cash flow from operating activities for Q1 2016 was CNY 9,685,749.82, a recovery from a negative cash flow of CNY 99,736,777.10 in the previous year[31] - Cash inflow from operating activities totaled CNY 1,924,006,516.05, while cash outflow was CNY 1,914,320,766.23, resulting in a net cash inflow[31] - Cash flow from investing activities was negative at CNY -3,973,288.97, compared to CNY -106,792,282.40 in the previous year, showing improvement[31] - Cash flow from financing activities resulted in a net outflow of CNY -1,556,152.50, compared to CNY -299,162,140.40 in the same period last year[31] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,185,105,753.19, a decrease of 1.12% compared to the end of the previous year[6] - Total current assets decreased to 3,637,627,447.95 from 3,684,496,766.72, with cash and cash equivalents slightly increasing to 493,577,361.28[20] - Total liabilities decreased to 2,698,021,860.18 from 2,809,243,569.68, indicating a reduction in financial obligations[22] - The company's total equity as of Q1 2016 was CNY 1,303,624,467.16, up from CNY 1,301,429,402.76 year-on-year[26] Inventory and Receivables - The company reported a 114.52% increase in notes receivable, reaching CNY 256,395,835.33, primarily due to an increase in accepted bills from medical clients[13] - Inventory decreased by 32.94% to CNY 599,977,694.35, attributed to the sale of winter stock accumulated at the end of the previous year[13] - Accounts receivable increased to 2,187,414,853.59 from 2,002,155,821.45, indicating a rise in credit sales[20] - Inventory decreased significantly to 599,977,694.35 from 894,639,457.07, reflecting improved inventory management[20] Expenses - Sales expenses decreased by 60.06% to 50,435,292.44, primarily due to the same exclusion of pharmaceutical assets[16] - Management expenses fell by 60.46% to 68,417,248.48, attributed to the exclusion of pharmaceutical assets from the consolidation scope[16] - Financial expenses decreased significantly by 92.05% to 674,744.36, due to reduced interest expenses and increased deposit interest income[16] - Sales expenses for Q1 2016 were CNY 50,435,292.44, down 60.1% from CNY 126,292,376.47 in the same period last year[28] - Management expenses decreased to CNY 68,417,248.48, down 60.5% from CNY 173,040,939.52 year-on-year[28] Shareholder Information - The total number of shareholders at the end of the reporting period was 20,169, with the largest shareholder, Harbin Pharmaceutical Group, holding 74.82% of the shares[10]